Impact of Targeted Therapy on the Quality of End-of-Life Care for Patients With Non-Small-Cell Lung Cancer: A Population-Based Study in Taiwan

Targeted therapy at EOL should be considered a quality-of-care indicator. Guidance in the cessation of targeted therapy and the ongoing monitoring of practice initiatives are warranted. The decision-making processes associated with EOL care also require further investigation.